Literature DB >> 23986567

The code structure of the p53 DNA-binding domain and the prognosis of breast cancer patients.

Keiko Sato1, Toshihide Hara, Masanori Ohya.   

Abstract

MOTIVATION: The tumor-suppressor gene TP53 mutations are diverse in the central region encoding the DNA-binding domain. It has not been clear whether the prognostic significance for survival in breast cancer patients is the same for all types of mutations. Are there specific types of mutations carrying a worse prognosis? To understand the correlation between the mutations in the gene encoding the DNA-binding domain and the prognosis of breast cancer, we studied the code structure of the DNA-binding domain of breast cancer patients by using various artificial codes in information transmission.
RESULTS: We indicated that the prognostic significance of all types of mutations in the DNA-binding domain is not the same, and that the DNA-binding domain having a certain code structure is important for estimating the prognosis of breast cancer patients. CONTACT: keiko@is.noda.tus.ac.jp or hara@is.noda.tus.ac.jp.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23986567     DOI: 10.1093/bioinformatics/btt497

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  2 in total

Review 1.  UGM: a more stable procedure for large-scale multiple testing problems, new solutions to identify oncogene.

Authors:  Chengyou Liu; Leilei Zhou; Yuhe Wang; Shuchang Tian; Junlin Zhu; Hang Qin; Yong Ding; Hongbing Jiang
Journal:  Theor Biol Med Model       Date:  2019-12-23       Impact factor: 2.432

2.  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.

Authors:  George Fountzilas; Eleni Giannoulatou; Zoi Alexopoulou; Flora Zagouri; Eleni Timotheadou; Kyriaki Papadopoulou; Sotiris Lakis; Mattheos Bobos; Christos Poulios; Maria Sotiropoulou; Aggeliki Lyberopoulou; Helen Gogas; George Pentheroudakis; Dimitrios Pectasides; Angelos Koutras; Christos Christodoulou; Christos Papandreou; Epaminontas Samantas; Pavlos Papakostas; Paris Kosmidis; Dimitrios Bafaloukos; Charisios Karanikiotis; Meletios-Athanassios Dimopoulos; Vassiliki Kotoula
Journal:  Oncotarget       Date:  2016-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.